Pharmaceutical companies and ophthalmic research

Thomas J. Liesegang; Andrew P. Schachat; Daniel A. Albert

doi:10.1016/j.ophtha.2004.12.014

Pharmaceutical companies and ophthalmic research

Thomas J. Liesegang, Andrew P. Schachat, Daniel A. Albert

Research output: Contribution to journal › Editorial › peer-review

Original language	English (US)
Pages (from-to)	363-365
Number of pages	3
Journal	Ophthalmology
Volume	112
Issue number	3
DOIs	https://doi.org/10.1016/j.ophtha.2004.12.014
State	Published - Mar 2005
Externally published	Yes

ASJC Scopus subject areas

Ophthalmology

Access to Document

10.1016/j.ophtha.2004.12.014

Cite this

@article{fd97830f3a66456fb67e09f27c4109fa,

title = "Pharmaceutical companies and ophthalmic research",

author = "Liesegang, {Thomas J.} and Schachat, {Andrew P.} and Albert, {Daniel A.}",

note = "Funding Information: Drs Liesegang and Albert have no financial interests to disclose. Dr Schachat disclosed his when he became Editor. 1 During the past 2 years, his activities have not changed substantially. His employer, the Johns Hopkins University, receives research grants that support a fraction of his time from the National Institutes of Health, Alcon, QLT, Inc., and Novartis. During the past 2 years he has provided consulting services for Berlex, Santen, Concurrent Pharmaceuticals, Neovista, Eyetech, and Pfizer. These agreements were reviewed and approved by his employer. ",

year = "2005",

month = mar,

doi = "10.1016/j.ophtha.2004.12.014",

language = "English (US)",

volume = "112",

pages = "363--365",

journal = "Ophthalmology",

issn = "0161-6420",

publisher = "Elsevier Inc.",

number = "3",

}

TY - JOUR

T1 - Pharmaceutical companies and ophthalmic research

AU - Liesegang, Thomas J.

AU - Schachat, Andrew P.

AU - Albert, Daniel A.

N1 - Funding Information: Drs Liesegang and Albert have no financial interests to disclose. Dr Schachat disclosed his when he became Editor. 1 During the past 2 years, his activities have not changed substantially. His employer, the Johns Hopkins University, receives research grants that support a fraction of his time from the National Institutes of Health, Alcon, QLT, Inc., and Novartis. During the past 2 years he has provided consulting services for Berlex, Santen, Concurrent Pharmaceuticals, Neovista, Eyetech, and Pfizer. These agreements were reviewed and approved by his employer.

PY - 2005/3

Y1 - 2005/3

UR - http://www.scopus.com/inward/record.url?scp=14644432995&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14644432995&partnerID=8YFLogxK

U2 - 10.1016/j.ophtha.2004.12.014

DO - 10.1016/j.ophtha.2004.12.014

M3 - Editorial

C2 - 15745760

AN - SCOPUS:14644432995

SN - 0161-6420

VL - 112

SP - 363

EP - 365

JO - Ophthalmology

JF - Ophthalmology

IS - 3

ER -

Pharmaceutical companies and ophthalmic research

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this